inactivated influenza vaccine Report issue

Vaccine Approved FDA
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Influenza vaccines, also known as flu shots, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. The United States Centers for Disease Control and Prevention (CDC) estimates that vaccination against influenza reduces sickness, medical visits, hospitalizations, and deaths. Immunized workers who do catch the flu return to work half a day sooner on average. Vaccine effectiveness in those over 65 years old remains uncertain due to a lack of high-quality research. Vaccinating children may protect those around them.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

a/17/ca/2009/38 (h1n1) | adimflu-w (h5n1) | adjuvanted h1n1 influenza vaccine | adjuvanted h1n1 influenza virus vaccine | adjuvanted h5n1 influenza virus vaccine | adjuvanted h5n1 pandemic influenza vaccine | adjuvanted inactivated novel swine origin a/h1n1 monovalent subunit influenza virus vaccine | adjuvanted inactivated whole virion h5n1 vaccine | adjuvanted seasonal trivalent inactivated influenza vaccine | adjuvanted trivalent subunit influenza vaccine | a/h1n1 influenza vaccine | a(h1n1) influenza vaccine | a/h1n1 influenza vlp vaccine | a/h1n1 pandemic influenza vaccine | a/h1n1 vaccine | a/h5n1 inactivated, split-virion influenza vaccine | a/h5n1 vaccine | a/indonesia/05/2005 (h5n1) like strain used (pr8-ibcdc-rg2) | anti-influenza vaccine | a/turkey h5n1 influenza vaccine | a/turkey h5n1 vaccine | butantan fragmented inactivated trivalent influenza vaccine | cell-derived a/h1n1 influenza ha vaccine | egg-derived h5n1 influenza vaccine | egg-derived trivalent inactivated subunit influenza vaccine | eh1n1 | eh1n1_f | eh5n1 | etiv-h5n1 | fcc h5n1 | fluad | fluad h5n1 | flucelvax | fluogen | flushield | fluviral | fluvirin | fluzone | fluzone quadrivalent | h1n1 influenza vaccine | h1n1 influenza virus vaccine | h1n1 pandemic influenza vaccine | h1n1 vaccine | h3n2 m2sr monovalent influenza vaccine | h3n2v inactivated subvirion influenza vaccine | h5n1 (6-2) aa ca recombinant | h5n1 influenza vaccine | h5n1 vaccine | h7n9 a/anhui/13 ca influenza virus vaccine | h7n9 influenza vaccine | h7n9 live influenza vaccine | h9n2 (6-2) aa ca reassortant | h9n2 influenza vaccine | h9n2 virosomal vaccine | hai-05 influenza vaccine | inactivated adjuvanted influenza vaccine | inactivated h1n1 vaccine | inactivated influenza a/h5n1 vaccine | inactivated influenza h1n1 vaccine | inactivated influenza h5n1 vaccine | inactivated influenza split vaccine | inactivated influenza vaccine | inactivated influenza vaccine trivalent types a and b | inactivated quadrivalent influenza vaccine | inactivated seasonal flu vaccine | inactivated seasonal influenza vaccine | inactivated split influenza vaccine | inactivated, split-virion influenza vaccine | inactivated split virus seasonal influenza vaccine | inactivated subvirion h7n9 influenza vaccine | inactivated trivalent influenza vaccine | inactivated vero cell based whole virus influenza a/h5n1 | inactived influenza vaccine | influenza a/california/04/2009 | influenza a/h1n1 2009 | influenza a h1n1 split virion vaccine | influenza a h1n1 whole virus vaccine | influenza a h7n7 vaccine | influenza a/vietnam/1203/2004 | influenza h1n1 monovalent vaccine | influenza h3n2 monocalen vaccine | influenza h5n1 virus monovalent vaccine | influenza h9n2 vaccine | influenza, live attenuated | influenza split vaccine | influenza vaccine | influenza vaccine, adjuvanted | influenza vaccines | influenza vaccine, split inactivated | influenza vaccine surface antigen | influenza vaccine trivalent inactivated | influenza vaccine, trivalent (tiv) | influenza vaccine (whole virion, inactivated) containing antigen of: a/vietnam/1203/2004 (h5n1) | influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) | influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain(a/brisbane/10/2010, wild type)a/switzerland/9715293/2013 (h3n2) - like strain(a/south australia/55/2014, wild type)b/phuket/3073/2013like strain(b/utah/9/2014, wild type) | influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 7.5 microgragms per 0.5 ml dose | influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) | influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) | influenza virus surface antigens, inactivated: a/viet nam/1194/2004 (h5n1) | influenza virus vaccine | influenza virus vaccine, h5n1 | influenza virus vaccine, monovalent a/h1n1 a/california/7/2009 nymc x-179a | influenza virus vaccine, monovalent a/h5n1 a/indonesia/05/2005 | influenza virus vaccine, monovalent a/h7n9 a/shanghai/2/2013 | influenza virus vaccine, reassorted | influenza virus (whole virion, inactivated), containing antigen of: a/vietnam/1203/2004 (h5n1) | live attenuated h7n9 a/anhui/13 ca influenza virus vaccine | monovalen inactivated h1n1 virus vaccine | monovalent h5n1 influenza vaccine | monovalent influenza a/h5n8 vaccine | monovalent influenza a/h7n9 virus vaccine | monovalent influenza subunit virion (h5n1) vaccine, a/indonesia/05/2005 | monovalent influenza subunit virion (inactive h5n1) vaccine | monovalent influenza subvirion vaccine, h7n7 | monovalent influenza vaccine | monovalent subvirion a/h1n1 influenza vaccine | nactived influenza vaccine | pandemic influenza a (h1n1) vaccine | pandemic influenza a/h1n1 vaccine | pandemic influenza a/h5n1 vaccine | pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) | pandemic influenza vaccine (h5n1 strain nibrg-14) | qiv | quadrivalent cell-culture based influenza vaccine | quadrivalent cell-culture influenza vaccine | quadrivalent inactivated influenza vaccine | quadrivalent inactivated influenza virus vaccine | quadrivalent influenza vaccine | quadrivalent influenza virus vaccine | quadrivalent subunit influenza virus vaccine | quadrivalent virosomal influenza vaccine | reassortant influenza virus (live attenuated) of the following four strains:a/california/7/2009 (h1n1)pdm09 - like strain(a/bolivia/559/2013, medi 255962)a/hong kong/4801/2014 (h3n2) - like strain(a/new caledonia/71/2014, medi 263122)b/brisbane/60/2008 - like strain(b/brisbane/60/2008, medi 228030)b/phuket/3073/2013 - like strain(b/phuket/3073/2013, medi 254977) | reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain | reassortant influenza virus (live attenuated) of the following strains: a/california/7/2009 (h1n1)pdm09 like strain, a/victoria/361/2011 (h3n2) like strain, b/massachusetts/2/2012 like strain | reassortant vaccine virus nymc x-179a | recombinant influenza ha vaccine (h5n1) | reverse genetic reassortant a/h9n2 influenza vaccine | rhao trivalent influenza vaccine | sanofi a(h1n1) vaccine | seasonal inactivated influenza vaccine | seasonal split influenza vaccine | seasonal trivalent inactivated influenza vaccine | s-oiv h1n1 vaccine | split inactivated a/california/7/2009 (h1n1) vaccine | split, inactivated, trivalent influenza vaccine | split influenza virus, inactivated, containing antigen* : a/california/7/2009 (h1n1)v like strain (x-179a) * produced in eggs | split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a) *propagated in eggs. | split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) | split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a | split influenza virus vaccine | split-virion, adjuvanted h1n1 vaccine | split-virion, adjuvanted h5n1 vaccine | split-virion, h1n1 vaccine | split virion, inactivated influenza vaccine | split-virion, non-adjuvanted h1n1 vaccine | subvirion a/h1n1 influenza vaccine | subvirion a/h5n1 influenza vaccine | subvirion inactivated influenza a/h9n2 | surface antigen, inactivated, adjuvanted influenza vaccine | swine a/h1n1 influenza vaccine | trivalent baculovirus-expressed influenza ha vaccine | trivalent cell-culture based influenza vaccine | trivalent inactivated flu vaccine | trivalent inactivated influenza vaccine | trivalent inactivated influenza virus vaccine | trivalent influenza split vaccine | trivalent influenza vaccine | trivalent influenza virus vaccine | trivalent seasonal influenza vaccine | trivalent split influenza vaccine | trivalent split influenza virus | trivalent subunit inactivated influenza vaccine | un-adjuvanted influenza a(h1n1) vaccine | vaccine h1n1 | vero cell-derived influenza vaccine | whole-virion, adjuvanted h1n1 vaccine | whole-virion, adjuvanted h5n1 vaccine | whole virion, inactivated containing antigen: a/california/07/2009 (h1n1)v | whole virion, inactivated, containing antigen*: a/vietnam/1194/2004 (h5n1) * produced in eggs

Organizations (436)

Research & Development (436)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (143)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (143)


 

Abdominal Neoplasms (Phase 1)

Abortion, Habitual (Phase 4)

Acute Coronary Syndrome (Phase 3)

Aged (Phase 1/Phase 2)

Aging (Phase 2)

Allergy and Immunology (Phase 4)

Anticoagulants (Phase 4)

Antiphospholipid Syndrome (Phase 4)

Arthritis, Juvenile (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Asthma (Phase 4)

Axial Spondyloarthritis (Phase 4)

Bone Marrow Transplantation (Phase 2)

Breast Neoplasms (Phase 2)

Central Nervous System Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 2)

Coronary Artery Disease (Phase 2/Phase 3)

COVID-19 (Phase 4)

Cytomegalovirus Infections (Phase 4)

Depression (Phase 4)

Dermatitis, Atopic (Early Phase 1)

Dermatology (Phase 4)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 4)

Dialysis (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Egg Hypersensitivity (Phase 1/Phase 2)

Encephalitis, Tick-Borne (Phase 4)

Enterovirus Infections (Phase 4)

Fever (Phase 3)

Graft Rejection (Phase 4)

Head and Neck Neoplasms (Phase 1/Phase 2)

Healthy Aging (Phase 1)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 3)

Heart Failure (Phase 4)

Hematologic Diseases (Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 2)

Hemodialysis, Home (Phase 3)

Hepatitis A (Phase 4)

Herpes Zoster (Phase 3)

HIV (Phase 4)

HIV Infections (Phase 4)

Humans (Phase 3)

Immune Complex Diseases (Phase 2)

Immune System Diseases (Phase 4)

Immunity (Phase 4)

Immunity, Cellular (Phase 4)

Immunity, Mucosal (Early Phase 1)

Immunization (Phase 2)

Immunocompromised Host (Phase 2)

Immunosenescence (Phase 2)

Immunosuppression Therapy (Phase 3)

Infant, Premature (Phase 4)

Infertility (Phase 4)

Inflammation (Phase 4)

Inflammatory Bowel Diseases (Phase 3)

Influenza A virus (Phase 4)

Influenza A Virus, H1N1 Subtype (Phase 4)

Influenza A Virus, H5N1 Subtype (Phase 4)

Influenza A Virus, H7N7 Subtype (Phase 1)

Influenza A Virus, H7N9 Subtype (Phase 2)

Influenza, Human (Phase 4)

Influenza in Birds (Phase 3)

Influenza Vaccines (Phase 4)

Injection Site Reaction (Phase 4)

Intestinal Neoplasms (Phase 4)

Kidney Failure, Chronic (Phase 4)

Kidney Transplantation (Phase 4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 4)

Live Birth (Phase 4)

Lung Diseases (Phase 3)

Lung Neoplasms (Phase 2)

Lung Transplantation (Phase 4)

Lupus Erythematosus, Systemic (Phase 4)

Lymphoma (Phase 3)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 4)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Malaria (Phase 2/Phase 3)

Melanoma (Phase 1)

MELAS Syndrome (Phase 4)

Meningococcal Vaccines (Phase 2)

Monoclonal Gammopathy of Undetermined Significance (Phase 2)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Myelodysplastic Syndromes (Phase 4)

Myocardial Infarction (Phase 4)

Neoplasms (Phase 4)

Neoplasms, Plasma Cell (Phase 4)

Organ Transplantation (Phase 3)

Orthomyxoviridae (Phase 3)

Orthomyxoviridae Infections (Phase 4)

Pain (Phase 4)

Pancreatic Neoplasms (Phase 2)

Pandemics (Phase 2)

Pediatrics (Phase 4)

Phobia, Social (Phase 4)

Plasma Cells (Phase 2)

Pneumococcal Infections (Phase 4)

Pneumonia (Phase 3)

Pneumonia, Pneumococcal (Phase 4)

Poliomyelitis (Phase 2/Phase 3)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Pregnancy (Phase 4)

Primary Immunodeficiency Diseases (Phase 1)

Prostatic Neoplasms (Phase 2)

Psychological Distress (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Quality of Life (Phase 4)

Renal Dialysis (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Respiratory Sounds (Phase 4)

Respiratory Syncytial Virus Infections (Phase 3)

Respiratory Tract Diseases (Phase 3)

Respiratory Tract Infections (Phase 4)

Rheumatic Diseases (Phase 4)

Rheumatology (Phase 2)

RNA Virus Infections (Phase 3)

Safety (Phase 4)

Sarcoidosis (Phase 3)

Sarcoidosis, Pulmonary (Phase 3)

Sclerosis (Phase 4)

Sjogren's Syndrome (Phase 4)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Streptococcus pneumoniae (Phase 4)

Stroke (Phase 4)

Systemic Vasculitis (Phase 4)

Tetanus (Phase 2/Phase 3)

Tissues (Phase 4)

Transplantation (Phase 4)

Transplants (Phase 4)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Typhoid Fever (Phase 4)

Vaccines (Phase 4)

Viral Vaccines (Phase 4)

Virus Diseases (Phase 4)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 963
  • # of Trial Organizations: 436

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue